Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D Willis

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Therapeutics and Clinical Risk Management|April 8, 2015
Alemtuzumab for the treatment of multiple sclerosisMark D Willis, Neil P Robertson
Current Neurology and Neuroscience Reports|August 4, 2016
Alemtuzumab for Multiple SclerosisMark D Willis, Neil P Robertson
Practical Neurology|June 27, 2024
Oligoclonal bandsMark D Willis, Karim L Kreft, Bethan Dancey
Journal of Neurology, Neurosurgery, and Psychiatry|July 17, 2025
Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologistMark D Willis, Ben Schroeder, Laura Marandino, et al.
International Ophthalmology|October 13, 2016
Alemtuzumab-induced remission of multiple sclerosis-associated uveitisMark D Willis, Trevor P Pickersgill, Neil P Robertson, et al.
Multiple Sclerosis and Related Disorders|March 17, 2020
Clinical observation during alemtuzumab administrationChristopher M Allen, Jenny J Feng, Mark D Willis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 12, 2018
Sarcoidosis following alemtuzumab treatment for multiple sclerosisMark D Willis, Ben Hope-Gill, Patrick Flood-Page, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 3, 2022
Contemporary study of multiple sclerosis disability in South East WalesKatharine Elizabeth Harding, Gillian Ingram, Emma Clare Tallantyre, et al.
European Journal of Neurology|November 19, 2024
Cerebral cortical encephalitis in adults with myelin oligodendrocyte glycoprotein antibody-associated disease: A national case seriesSamuel Pace, Silvia Messina, Bo Chen, et al.
Scientific Reports|October 18, 2016
Targeted suppression of autoreactive CD8<sup>+</sup> T-cell activation using blocking anti-CD8 antibodiesMathew Clement, James A Pearson, Stephanie Gras, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Therapeutics and Clinical Risk Management|April 8, 2015
Alemtuzumab for the treatment of multiple sclerosisMark D Willis, Neil P Robertson
Current Neurology and Neuroscience Reports|August 4, 2016
Alemtuzumab for Multiple SclerosisMark D Willis, Neil P Robertson
Practical Neurology|June 27, 2024
Oligoclonal bandsMark D Willis, Karim L Kreft, Bethan Dancey
Journal of Neurology, Neurosurgery, and Psychiatry|July 17, 2025
Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologistMark D Willis, Ben Schroeder, Laura Marandino, et al.
International Ophthalmology|October 13, 2016
Alemtuzumab-induced remission of multiple sclerosis-associated uveitisMark D Willis, Trevor P Pickersgill, Neil P Robertson, et al.
Multiple Sclerosis and Related Disorders|March 17, 2020
Clinical observation during alemtuzumab administrationChristopher M Allen, Jenny J Feng, Mark D Willis, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 12, 2018
Sarcoidosis following alemtuzumab treatment for multiple sclerosisMark D Willis, Ben Hope-Gill, Patrick Flood-Page, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 3, 2022
Contemporary study of multiple sclerosis disability in South East WalesKatharine Elizabeth Harding, Gillian Ingram, Emma Clare Tallantyre, et al.
European Journal of Neurology|November 19, 2024
Cerebral cortical encephalitis in adults with myelin oligodendrocyte glycoprotein antibody-associated disease: A national case seriesSamuel Pace, Silvia Messina, Bo Chen, et al.
Scientific Reports|October 18, 2016
Targeted suppression of autoreactive CD8<sup>+</sup> T-cell activation using blocking anti-CD8 antibodiesMathew Clement, James A Pearson, Stephanie Gras, et al.
Pageof 1